ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 214 filers reported holding ROYALTY PHARMA PLC in Q1 2021. The put-call ratio across all filers is 1.03 and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,260,070 | -20.5% | 1,225,500 | -9.9% | 0.03% | -7.1% |
| Q2 2023 | $41,815,622 | -17.1% | 1,360,300 | -2.9% | 0.03% | -20.0% |
| Q1 2023 | $50,456,412 | -10.2% | 1,400,400 | -1.5% | 0.04% | -12.5% |
| Q4 2022 | $56,169,776 | -7.4% | 1,421,300 | -5.8% | 0.04% | -7.0% |
| Q3 2022 | $60,640,000 | -4.0% | 1,509,210 | +0.4% | 0.04% | 0.0% |
| Q2 2022 | $63,166,000 | +8.9% | 1,502,510 | +1.0% | 0.04% | +30.3% |
| Q1 2022 | $57,985,000 | +12.1% | 1,488,310 | +14.6% | 0.03% | +6.5% |
| Q4 2021 | $51,746,000 | +104.8% | 1,298,510 | +85.8% | 0.03% | +93.8% |
| Q3 2021 | $25,262,000 | -13.7% | 699,010 | -2.2% | 0.02% | -11.1% |
| Q2 2021 | $29,288,000 | -0.0% | 714,510 | +6.4% | 0.02% | -10.0% |
| Q1 2021 | $29,300,000 | +36.3% | 671,700 | +56.4% | 0.02% | +33.3% |
| Q4 2020 | $21,496,000 | – | 429,500 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |